First Trust Advisors LP boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,196,606 shares of the medical research company's stock after acquiring an additional 65,211 shares during the period. First Trust Advisors LP owned 0.22% of Amgen worth $504,381,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. State Street Corp lifted its holdings in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company's stock worth $1,952,156,000 after buying an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new stake in Amgen in the second quarter worth about $1,831,903,000. Finally, Amundi grew its stake in Amgen by 15.2% in the second quarter. Amundi now owns 3,890,189 shares of the medical research company's stock valued at $1,408,715,000 after purchasing an additional 512,883 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently commented on AMGN shares. Jefferies Financial Group reiterated a "hold" rating and set a $410.00 price target on shares of Amgen in a report on Wednesday, September 23rd. Weiss Ratings upgraded Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. Oppenheimer reissued an "outperform" rating on shares of Amgen in a research report on Friday, October 23rd. Barclays boosted their price objective on shares of Amgen from $400.00 to $430.00 and gave the company an "equal weight" rating in a research report on Monday, November 16th. Finally, Freedom Broker cut Amgen from a "buy" rating to a "hold" rating and raised their target price for the company from $450.00 to $470.00 in a research note on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $428.62.
View Our Latest Research Report on AMGN
Amgen Stock Down 0.8%
AMGN opened at $435.52 on Friday. The stock has a fifty day moving average of $430.44 and a 200-day moving average of $383.81. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99. The company has a market capitalization of $235.58 billion, a P/E ratio of 25.26, a P/E/G ratio of 3.03 and a beta of 0.43.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping the consensus estimate of $5.79 by $0.66. The firm had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the business earned $5.64 EPS. On average, equities analysts expect that Amgen Inc. will post 23.44 EPS for the current year.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen's payout ratio is currently 58.47%.
Amgen Company Profile
(
Free Report)
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.